WallStreetZenWallStreetZen

NASDAQ: TRDA
Entrada Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for TRDA

Based on 2 analysts offering 12 month price targets for Entrada Therapeutics Inc

Min Forecast
$20.00+76.83%
Avg Forecast
$20.00+76.83%
Max Forecast
$20.00+76.83%

Should I buy or sell TRDA stock?

Based on 2 analysts offering ratings for Entrada Therapeutics Inc.

Strong Buy
Strong Buy
1 analysts 50%
Buy
1 analysts 50%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although TRDA's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates TRDA as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +7.53% per year. Learn More

Be the first to know when Wall Street analysts revise their TRDA stock forecasts and price targets.

TRDA stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-02-18
lockedlocked$00.00+00.00%2026-02-11

1 of 1

Forecast return on equity

Is TRDA forecast to generate an efficient return?

Company
-24.24%
Industry
68.21%
Market
181.01%
TRDA's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is TRDA forecast to generate an efficient return on assets?

Company
-19.66%
Industry
31.86%
TRDA is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

TRDA earnings per share forecast

What is TRDA's earnings per share in the next 3 years based on estimates from 9 analysts?

Avg 1 year Forecast
-$3.95
Avg 2 year Forecast
-$3.85
Avg 3 year Forecast
-$3.56

TRDA revenue forecast

What is TRDA's revenue in the next 3 years based on estimates from 9 analysts?

Avg 1 year Forecast
$35.6M+39.97%
Avg 2 year Forecast
$53.7M+111.07%
Avg 3 year Forecast
$68.0M+167.53%
TRDA's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

TRDA revenue growth forecast

How is TRDA forecast to perform vs Biotechnology companies and vs the US market?

Company
39.34%
Industry
35.63%
Market
13.32%
TRDA's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
TRDA's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

TRDA vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
TRDA$11.31$20.00+76.83%Strong Buy
ALT$3.34$17.33+418.95%Strong Buy
IPSC$2.42$3.00+23.97%Buy
FDMT$8.61$32.60+278.63%Strong Buy
KZIA$7.48$19.00+154.01%Strong Buy
View Top Biotech Stocks

Entrada Therapeutics Stock Forecast FAQ

Is Entrada Therapeutics Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: TRDA) stock is to Strong Buy TRDA stock.

Out of 2 analysts, 1 (50%) are recommending TRDA as a Strong Buy, 1 (50%) are recommending TRDA as a Buy, 0 (0%) are recommending TRDA as a Hold, 0 (0%) are recommending TRDA as a Sell, and 0 (0%) are recommending TRDA as a Strong Sell.

If you're new to stock investing, here's how to buy Entrada Therapeutics stock.

What is TRDA's earnings growth forecast for 2026-2028?

(NASDAQ: TRDA) Entrada Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.93%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 36.08%.

Entrada Therapeutics's earnings in 2026 is -$143,750,000.On average, 9 Wall Street analysts forecast TRDA's earnings for 2026 to be -$151,291,948, with the lowest TRDA earnings forecast at -$174,461,614, and the highest TRDA earnings forecast at -$99,692,351. On average, 8 Wall Street analysts forecast TRDA's earnings for 2027 to be -$147,283,581, with the lowest TRDA earnings forecast at -$190,219,438, and the highest TRDA earnings forecast at -$77,583,160.

In 2028, TRDA is forecast to generate -$136,207,929 in earnings, with the lowest earnings forecast at -$181,965,340 and the highest earnings forecast at -$47,434,264.

What is TRDA's revenue growth forecast for 2026-2028?

(NASDAQ: TRDA) Entrada Therapeutics's forecast annual revenue growth rate of 39.34% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.63%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.32%.

Entrada Therapeutics's revenue in 2026 is $25,421,000.On average, 9 Wall Street analysts forecast TRDA's revenue for 2026 to be $1,362,232,425, with the lowest TRDA revenue forecast at $562,779,401, and the highest TRDA revenue forecast at $2,411,911,719. On average, 9 Wall Street analysts forecast TRDA's revenue for 2027 to be $2,054,221,383, with the lowest TRDA revenue forecast at $953,738,805, and the highest TRDA revenue forecast at $3,416,874,935.

In 2028, TRDA is forecast to generate $2,603,677,843 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $6,914,146,928.

What is TRDA's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: TRDA) forecast ROA is -19.66%, which is lower than the forecast US Biotechnology industry average of 31.86%.

What is TRDA's Price Target?

According to 2 Wall Street analysts that have issued a 1 year TRDA price target, the average TRDA price target is $20.00, with the highest TRDA stock price forecast at $20.00 and the lowest TRDA stock price forecast at $20.00.

On average, Wall Street analysts predict that Entrada Therapeutics's share price could reach $20.00 by Feb 18, 2027. The average Entrada Therapeutics stock price prediction forecasts a potential upside of 76.83% from the current TRDA share price of $11.31.

What is TRDA's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: TRDA) Entrada Therapeutics's current Earnings Per Share (EPS) is -$3.47. On average, analysts forecast that TRDA's EPS will be -$3.95 for 2026, with the lowest EPS forecast at -$4.56, and the highest EPS forecast at -$2.60. On average, analysts forecast that TRDA's EPS will be -$3.85 for 2027, with the lowest EPS forecast at -$4.97, and the highest EPS forecast at -$2.03. In 2028, TRDA's EPS is forecast to hit -$3.56 (min: -$4.75, max: -$1.24).

What is TRDA's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: TRDA) forecast ROE is -24.24%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.